Clinical Landscape of Primary CNS Lymphoma MRI

Primary central nervous system lymphoma represents an aggressive extranodal non-Hodgkin lymphoma restricted to the brain, leptomeninges, eyes, or spinal cord. Historically, diagnostic workflows have relied on neuroimaging alongside stereotactic biopsy to guide prompt systemic chemotherapy. Modern clinical management emphasizes that primary CNS lymphoma MRI characteristics reflect profound underlying biological heterogeneity. Most lesions demonstrate homogeneous contrast enhancement and restricted diffusion due to dense cellular packing. However, routine neuroimaging historically provided limited insights into underlying molecular somatic mutations. Consequently, neuro-oncologists and hematologists continue to seek non-invasive methods to uncover actionable tumor biology before initiating cytotoxic regimens. In precision oncology, identifying specific genomic signatures can drastically alter therapeutic paradigms. Specifically, activating mutations in B-cell receptor pathway drivers influence sensitivity to novel small-molecule inhibitors. Bruton tyrosine kinase inhibitors, for example, have demonstrated remarkable biological activity in specific genomic subsets. Therefore, bridging anatomical imaging with molecular genetics through advanced radiogenomics offers an attractive diagnostic frontier. Non-invasive imaging biomarkers could accelerate risk stratification, guide salvage options, and enrich clinical trials without subjecting frail patients to repeat invasive procedures.

Pre-Planned Framework and Radiogenomic Hypotheses

To interrogate this diagnostic frontier, investigators evaluated the public UCSF-PCNSL cohort consisting of 146 patients. Among these individuals, 63 had comprehensive molecular profiling available via the UCSF500 next-generation sequencing cancer panel. Rather than running unconstrained high-dimensional feature mining, the researchers formulated a pre-planned clinical framework. This rigorous methodology avoided opportunistic p-hacking and spurious statistical associations. Specifically, the authors defined four biologically driven MRI biomarker-to-genotype pairings in advance of statistical calculations. The principal hypothesis evaluated the association between CD79B mutation status and the enhancing-core tumor habitat. Furthermore, the team assessed whether imaging habitats could identify the broader MCD-like genomic subtype. This molecular category frequently harbors co-occurring MYD88 and CD79B alterations that confer sensitivity to Bruton tyrosine kinase inhibition. Additionally, the investigators evaluated secondary hypotheses pairing TP53 mutations with peritumoral edema ratios and CDKN2A/B deletions with overall tumor necrosis. By testing clinically meaningful pairings, the study aimed to generate biologically interpretable imaging biomarkers. Clinicians recognize that TP53 and CDKN2A/B alterations portend inferior survival in aggressive B-cell lymphomas. Thus, pre-specifying these specific biological targets grounded the radiogenomic exploration in sound clinical oncology.

Enhancing-Core Habitat and CD79B Association

The investigators segmented lesions into sub-compartments termed tumor habitats using routine multiparametric magnetic resonance imaging sequences. They specifically quantified the enhancing-core fraction, designated as habitat 1, alongside non-enhancing peritumoral fluid-attenuated inversion recovery hyperintensity. Consequently, the study evaluated whether localized vascular permeability and tumor cellular density correlated with distinct genomic profiles. In testing the primary hypothesis, the authors identified a significantly higher enhancing-core fraction in CD79B-mutant tumors. Specifically, patients harboring CD79B pathogenic variants displayed a median enhancing fraction of 0.190 compared to 0.124 in wild-type tumors. The statistical analysis demonstrated a Cliff's delta effect size of +0.34 with a 95% bootstrap confidence interval of +0.04 to +0.63. Moreover, the rank receiver operating characteristic area under the curve reached 0.67, yielding an unadjusted p-value of 0.015. These quantitative findings indicate that CD79B alterations correlate with compact, avidly enhancing central tumor components. In contrast, tumors without these mutations frequently exhibit more diffuse, infiltrative architectural boundaries. Therefore, the enhancing-core habitat emerged as the leading non-invasive imaging candidate for CD79B enrichment.

Secondary Genomic Signals and Scanner Reproducibility

Beyond the primary CD79B hypothesis, the investigators examined secondary molecular associations across the neuroimaging dataset. Notably, the third pre-planned hypothesis demonstrated directional consistency between TP53 mutation status and surrounding edema. Patients harboring TP53 mutations exhibited a higher FLAIR-to-T1-contrast ratio, yielding a Cliff's delta of +0.31 with an unadjusted p-value of 0.049. Biologically, this finding suggests that p53-driven genomic instability may promote greater peritumoral microvascular leakage or deeper parenchymal invasion. However, the analyses evaluating the combined MCD-like genotype and CDKN2A/B deletions failed to demonstrate statistically significant associations. To verify analytical stability, the research team implemented rigorous leave-one-batch-out cross-validation across six diverse MRI scanner batches. Remarkably, the CD79B enhancing-core association preserved its positive direction across all six scanner cohorts. Furthermore, habitat-based biomarkers outperformed simplistic whole-lesion volumetric measurements in cross-validated performance benchmarks. This technical robustness highlights that habitat spatial partitioning captures true underlying physiological signals rather than random acquisition artifacts. Consequently, multi-habitat profiling provides superior biological fidelity compared to traditional lesion dimension tracking.

Multiple Testing Constraints and Translational Outlook

Although initial statistical comparisons yielded promising candidate signals, adjusting for multiple testing altered the definitive conclusions. When the researchers applied rigorous family-wise error rate corrections across the four pre-specified hypotheses, neither biomarker reached the 0.05 alpha threshold. Therefore, the authors correctly emphasize that these intriguing findings remain strictly exploratory and hypothesis-generating. Past machine-learning studies frequently overfitted thousands of uncurated imaging textures to tiny retrospective cohorts, producing non-reproducible clinical claims. In contrast, this study prioritized biological plausibility, effect sizes, and scanner robustness over aggressive statistical claims. From a practical neuro-oncology standpoint, candidate imaging biomarkers could reshape therapeutic workflows if validated in independent prospective cohorts. Currently, clinicians encounter elderly or debilitated lymphoma patients who cannot safely undergo invasive brain biopsies. In such delicate scenarios, validated radiogenomic markers could provide non-invasive biological enrichment for targeted therapeutic trials with Bruton tyrosine kinase inhibitors. Nevertheless, standard histopathologic confirmation and tissue molecular profiling remain mandatory clinical cornerstones today. Ultimately, translating computational habitat imaging into actionable bedside tools promises to refine personalized treatment paradigms in neuro-oncology.

What was the primary objective of this primary CNS lymphoma radiogenomic study?

The study evaluated whether routine multiparametric MRI biomarkers could non-invasively identify actionable genetic alterations in primary CNS lymphoma. Specifically, investigators tested a pre-planned clinical framework analyzing candidate associations with CD79B mutations, the MCD-like genotype, TP53 alterations, and CDKN2A/B deletions to facilitate future patient stratification for targeted Bruton tyrosine kinase inhibitor therapy.

Why is identifying the CD79B mutation clinically significant in lymphoma?

CD79B encodes a critical B-cell receptor subunit frequently mutated in aggressive lymphomas alongside MYD88. This co-occurrence characterizes the MCD subtype, which exhibits chronic active B-cell receptor signaling and remarkable therapeutic vulnerability to Bruton tyrosine kinase inhibitors. Non-invasive identification could potentially help oncologists prioritize candidates for targeted therapy or clinical trial enrolment.

Can these MRI biomarkers replace surgical tissue biopsy in current practice?

No, these imaging biomarkers cannot replace histopathological biopsy in current clinical practice. After rigorous adjustment for multiple testing across the four pre-specified hypotheses, the statistical associations did not meet significance thresholds. Consequently, these findings represent exploratory, hypothesis-generating insights that require prospective validation across independent multicenter cohorts before clinical adoption.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

1. García-Hidalgo C et al. Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. J Neurooncol. 2026 May 29. doi: 10.1007/s11060-026-05658-5. PMID: 42213292.


2. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-2418.


3. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017;31(6):833-843.


4. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378(15):1396-1407.